Form 4: Intra-Cellular Therapies Director Rory B. Riggs Acquires Shares

Director Rory B. Riggs of Intra-Cellular Therapies, Inc. acquired 215 shares of common stock on December 31, 2024.

Summary

• Rory B. Riggs, a director at Intra-Cellular Therapies, Inc., purchased 215 shares of the company's common stock.
• The transaction occurred on December 31, 2024.
• The price per share was $83.52.
• Following this transaction, Mr. Riggs directly owns 131,512 shares of Intra-Cellular Therapies stock.

Sentiment

Score: 6

Explanation: The document is a routine SEC filing of a director purchasing shares. It is a positive sign but not a major event.

Positives

• A director's purchase of company stock can be seen as a positive signal of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade their company's stock. It provides transparency into the transactions of company directors.

Comparison to Industry Standards

• SEC Form 4 filings are a standard practice for publicly traded companies in the United States.
• The reporting requirements are consistent across all companies and are designed to ensure transparency in insider trading.
• The transaction is typical for a director and the number of shares is not unusual.

Stakeholder Impact

• The purchase of shares by a director may be viewed positively by shareholders, indicating confidence in the company's prospects.

Key Dates

Keywords

Intra-Cellular Therapies, ITCI, Rory B. Riggs, stock acquisition, director, insider trading, SEC Form 4